Essential hypertension onset in a 12-year-old adolescent by Mohd Shaiful Ehsan Shalihin, et al.
Essential Hypertension Onset in a 12-Year-Old Adolescent
 (Permulaan Tekanan Darah Tinggi pada Remaja 12 Tahun)
Mohd Shaiful Ehsan Shalihin*, Zulkifli Harun & Iskandar Firzada Osman
ABSTRACT
Essential hypertension in adolescents is increasing in trend worldwide in view of increasing prevalence of childhood 
obesity and sedentary lifestyle. Generally, secondary hypertension is suspected if it occurs at pre-pubertal age or 
presented with resistant hypertension. We reported a case of 12-year-old adolescent male diagnosed with essential 
hypertension during opportunistic screening with suboptimal blood pressure control at primary care. Poor response of 
his blood pressure control despite his compliance to medications had cause him emotional distress. We referred this 
child for assessment of secondary hypertension but it turned out to be negative. Surprisingly, his blood pressure 
responded well with prazosin and diltiazem combination during adjustment period prior to renovascular assessment. 
His hypertension is well controlled till now. This case proved that essential hypertension is still possible in early non-
morbid obese adolescent despite negative family history of hypertension. Individualised treatment should be adapted 
rather than questioning the compliance of the adolescent.
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ABSTRAK
Kes tekanan darah tinggi dalam kalangan remaja semakin meningkat oleh kerana peningkatan kes kegemukan dan 
pengamalan gaya hidup yang tidak sihat sejak daripada usia kanak-kanak. Secara umumnya, tekanan darah akibat 
punca kesihatan yang lain perlulah dikenal pasti terutama jika tekanan darah tinggi terjadi pada usia sebelum akil 
baligh atau pada keadaan tekanan darah yang sukar untuk dikawal.  Kami sertakan laporan kes berkaitan remaja lelaki 
berusia 12 tahun yang telah dikenal pasti mengalami tekanan darah tinggi yang sukar untuk dikawal secara optimum 
di klinik kesihatan. Kawalan tekanan darah yang tidak berkesan biarpun telah mematuhi pengambilan ubat yang 
disyorkan telah mengakibatkan tekanan emosi kepada remaja ini. Justeru kami telah merujuk remaja ini kepada pihak 
hospital namun rawatan susulan mendapati remaja ini tidak mempunyai masalah lain berkaitan darah tinggi beliau. 
Tanpa dijangka, bacaan tekanan darahnya menjadi terkawal dengan pengambilan ubat prazosin dan diltiazem sebelum 
menjalani penilaian fungsi saluran darah buah pinggang. Ternyata tekanan darahnya menjadi terkawal sehingga 
sekarang. Kes ini berjaya membuktikan tekanan darah tinggi boleh terjadi pada usia awal remaja yang tiada masalah 
obesiti mahupun tiada sejarah darah tinggi keturunan. Pencarian ubat darah tinggi yang sesuai untuk kawalan darah 
tinggi dalam kalangan remaja perlulah menjadi keutamaan berbanding mempertikaikan kejujuran remaja dalam 
mengambil ubat seperti yang telah ditetapkan.  
Kata kunci: Darah tinggi; diltiazem; prazosin; remaja
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Introduction
The prevalence of hypertension in adolescents is increasing 
in trend due to the sedentary lifestyle, which imposed high 
cardiovascular risks at a young age (Anyaegbu & 
Dharnidharka 2014; Flynn et al. 2017; Matoo 2019a). It is 
mostly related with essential hypertension and metabolic 
syndrome (Anyaegbu & Dharnidharka 2014;  Flynn et al. 
2017; Mattoo 2019a). The child and adolescent with chronic 
illness usually have been labelled as a high-risk group for 
non-compliance towards medications and follow up (Eden 
et al. 2011; Mattoo 2019b). This stigma can lead to poor 
self-esteem and demotivation, which will finally end up with 
treatment failure (Compas et al. 2012; Raj & Kumar 2010; 
Santos et al. 2016). The stigma of non-compliance is evolved 
further whenever the child is not responsive to the first line 
of antihypertensive agents. However, healthcare providers 
should be aware of the principle of individualised treatment 
in which patients may respond differently to different 
antihypertensive agents. Even though consensus has 
highlighted angiotensin converting enzyme inhibitor group 
as the drug of choice, healthcare providers should also be 
able to modify medications accordingly, since an 
individualised response to certain drugs is unpredictable 
(Flynn et al. 2017; Rao 2016). This includes the possibility 
of using alpha blocker and non-dihydropyridines, even in 
adolescents (Rodriguez-Cruz 2017).
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Case Report
We report a case of 12-year-old adolescent male diagnosed 
with hypertension during opportunistic screening, with 
suboptimal blood pressure control at primary care. He is 
overweight with a BMI of 27.0 kg/m2. He is a non-smoker. 
He has good academic performance with good family 
support. All his family members are normotensive with 
ideal body weight. He has no clinical and biochemical 
features of secondary hypertension from the initial 
assessment. He has emotional distress displayed by a lack 
of motivation to attend the clinic for follow-up due to poor 
response of his blood pressure control. He also blamed his 
overweight as the main reason for his hypertension. After 
adequate counselling, we managed to motivate the parents 
and the adolescent for further referral including to the 
dietitian and occupational therapist for appropriate diet and 
weight reduction prescription. We also taught him on a 
relaxation technique and behaviour modification in order 
to increase his self-esteem and confidence level. In view 
of worsening blood pressure control despite good 
compliance on different recommended antihypertensive 
drugs and lifestyle modification, we referred this patient 
for further work-up and shared care with the endocrinology 
team. However, the results turn up to be normal. 
Surprisingly, his blood pressure responded well with 
prazosin and diltiazem during the adjustment period prior 
to assessment for renovascular hypertension. His 
hypertension is well controlled until now. Table 1 shows 
the result of his main investigations for his hypertension 
assessment.
TABLE 1. Hypertension assessment result for this adolescent
Investigation Result
UFEME Normal (no proteinuria)
Creatinine 63.0umol/l
Potassium 3.8 mmol/l
ECG Sinus rhythm, no ischemic changes or 
abnormality
U/S KUB/Doppler Normal
Serum Cortisol 235.8 nmol/l
Results and Discussion
Hypertension has been reported to occur even at younger 
age group in our country. Based on our national health and 
morbidity survey, the prevalence of known hypertension 
among adolescent is 6.7%, which is higher compared to 
the worldwide data of those ages less than 18 (Bell et al. 
2019; Tahir et al. 2015). The initial approach to hypertension 
in adolescents is similar to adults. Screening for secondary 
causes should be done via adequate history taking, physical 
examination and individualized baseline investigation 
(Flynn et al. 2017; Mattoo 2019a; Rao 2016; Rodriguez-
Cruz 2017). Not all the recommended lists of investigations 
for secondary hypertension screening need to be done in 
children and adolescents. This is because the tests should 
act as a complementary investigation in response to the 
initial thorough clinical assessment and physical findings 
rather than being the main decision tool (Flynn et al. 2017; 
Matoo 2019a, 2019b; Neutze & Viera 2010). Furthermore, 
the sensitivity and specificity of the tests are low, which 
will not benefit the mass screening in terms of its cost 
effectiveness. Excessive investigations will also lead to 
further emotional burden to the child and parents in view 
of frequent blood takings and imaging procedures that will 
consume more time, energy and cause more worries 
(Compas et al. 2012;  Flynn et al. 2017; Rao 2016; 
Rodriguez-Cruz 2017; Santos et al. 2016). Therefore, 
clinical correlation during the initial assessment is indeed 
superior in deciding specific investigation. Criteria which 
favours primary hypertension in our case included the age 
of onset of more than 10-years old with underlying 
overweight despite no family history of similar co-
morbidity.
In any case of hypertension, initial assessment of 
investigation aims to identify features suggestive of target 
organ damage and possible clues to secondary hypertension 
(Anyaegbu & Dharnidharka 2014; Eden et al. 2011;  Flynn 
et al. 2017; Matoo 2019a, 2019b; Neutze & Viera 2010). 
In our case, all his investigations’ values are within the 
normal range. Surprisingly, his blood pressure control is 
still sub-optimal despite several medications had been 
changed and introduced. Because of that, his compliance 
towards medications was questioned. It has caused the 
adolescent to be emotionally disturbed and started to 
default his treatment. Previous studies have shown that 
excessive rules and high demand for changes in a child 
and adolescent with a chronic illness will lead to emotional 
instability and depression (Compas et al. 2012; Santos et 
al. 2016). In our case, eventually, we were able to regain 
back his confidence and self-esteem by engaging well with 
his opinion and worries. We also praised and assigned him 
as the decision maker and empowered him with blood 
pressure monitoring at home. These are among the 
techniques that will indirectly involve the adolescent with 
the management team and reduce their negative thoughts 
(Compas et al. 2012; Santos et al. 2016). However, we 
realized that his blood pressure remains the same. Given 
that overweight may contribute to hypertension through 
the development of renal disease and increment of volume 
expansion by activation of the renal-angiotensin system, 
we decided to concentrate on him to lose weight (Jiang et 
al. 2016). However, this weight reduction plan later causes 
more distress to him. By involving the dietician together 
with the occupational therapist to coach him in anger 
management and anxiety control, he was able to lose his 
weight effectively. He has benefited good support from his 
parents and family members. Indeed, discussion and 
psychosocial support are among the most important 
prognostic factor for children with chronic illness (Compas 
et al. 2012; Santos et al. 2016).
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The approach in managing adolescents with chronic 
illness needs to include soft skills and great listening 
attitude towards them, rather than monotonous advice by 
the healthcare providers (Compas et al. 2012; Flynn et al. 
2017;  Raj & Kumar 2010; Rao 2016; Rodriguez-Cruz 
2017; Santos et al. 2016). The treatment goals need to be 
realistic, achievable and staggered in longer duration. One 
to one consultation by seeing the adolescent alone without 
any family members’ interruption for a given period is very 
important so that he could feel free and comfortable for us 
to explore any sensitive issues, including his actual 
compliance with the medications in a non-judgemental 
manner. This is important in order to gain the adolescent’s 
trust and avoid the adolescent from being embarrassed in 
front of others (Compas et al. 2012; Santos et al. 2016). 
Furthermore, the adolescent will have the freedom to 
answer and discuss his worries without the parents 
interrupting the conversation.
At a point where we managed to gain back his trust, 
we would expect the response to his treatment to be 
improved (Compas et al. 2012;  Flynn et al. 2017;  Raj & 
Kumar 2010; Rao 2016; Rodriguez-Cruz 2017; Santos et 
al. 2016). However, in our case, several medications have 
been given and tapered without any improvement. His 
blood pressure remains at systolic value (SBP) ranges of 
150-154 mmHg and diastolic value (DBP) ranges of 90-100 
mmHg despite being on two drugs combination. He was 
previously already on angiotensin converting enzyme 
inhibitor, calcium channel blocker and beta blocker. We 
decided to refer him to a tertiary centre for shared care and 
secondary hypertension workup. However, the assessment 
favoured the possibility of essential hypertension rather 
than secondary hypertension. In view of no contraindication 
of specific antihypertensive drugs in adolescents, we 
decided to change his medications to alpha blocker and 
non-dihydropyridine calcium channel blocker combination 
therapy. To our surprise, his blood pressure is well 
controlled, and we have continued this drugs combination 
until now. Prazosin is an alpha blocker which controls 
blood pressure by reducing arterial tone leading to 
vasodilatation through the peripheral postsynaptic blockade 
(Schmidt & Akbar 2018). Meanwhile, verapamil is a non-
dihydropyridine calcium channel blockers which inhibit 
the influx of extracellular calcium across both myocardial 
and vascular smooth muscle cell membranes, therefore, 
prevents the contractile processes of myocardial smooth 
muscle cells, resulting in dilation of the coronary and 
systemic arteries (Schmidt & Akbar 2018). In addition, 
both drugs reduce total peripheral resistance, systemic 
blood pressure and afterload pressure, which may 
contribute to the significant blood pressure reduction in 
this case study.
Our case has proved the role of alpha blocker and 
non-dihydropyridine in controlling blood pressure in 
adolescents. Further study needs to be done to assess the 
secondary end points benefit of these drugs, especially in 
younger group of patients (Flynn et al. 2017; Messerli et 
al. 2010; Rao 2016; Rodriguez-Cruz 2017). Despite being 
unlisted under the first-line therapy group, alpha blocker 
and non-dihydropyridine calcium channel blocker still have 
a role in controlling blood pressure (Flynn et al. 2017; 
Messerli et al. 2010; Rao 2016; Rodriguez-Cruz 2017). 
Previously, alpha blocker had more roles in patients with 
underlying lower urinary tract symptoms and added therapy 
in resistant hypertension. This is because of its inferior role 
in cardiovascular disease as proven in Antihypertensive 
and Lipid-Lowering Treatment to Prevent Heart Attack 
Trial (ALLHAT trial) (Messerli et al. 2010). Meanwhile, 
non-dihydropyridines is used for arrhythmia disorder, such 
as supraventricular tachycardia and migraine prophylaxis. 
However, our case study showed that their role is also 
important as effective antihypertensive medications. 
Therefore, further study needs to be done to assess the extra 
benefits of these drugs in hypertension among adolescents. 
Conclusion
Our case study demonstrates that essential hypertension is 
possible in early adolescent despite negative family history 
of hypertension, in which opportunistic blood pressure 
measurement is highly beneficial as a hypertension 
screening tool, beginning at the age of three years old as 
suggested by the latest clinical practice guideline. Even 
though alpha blockers and non-dihydropyridine calcium 
channel blockers are not among the recommended initial 
antihypertensive agents, treatments should be individualised 
and they still play a role in those with resistant hypertension 
in adolescents, provided that appropriate assessment has 
been done either in primary or tertiary care centres for 
secondary causes. Exploring compliance in adolescents 
should be done in a respectful manner in order to maintain 
their motivation and self-esteem to comply with the 
treatment. The possibility of underlying depression 
secondary to the burden of the chronic disease needs to be 
ruled out if the treatment outcome is still suboptimal.
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